Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 18;4:1–16. doi: 10.1016/j.omtm.2016.11.001

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Overall Survival and Absence of Donor-Derived Malignancies in LV-Treated Mice

(A) Kaplan-Meier survival curves for primary (left) and secondary (right) recipients during the 16-week post-BM transplant periods. (B) Pie chart showing tumor incidence as a percentage of all (primary and secondary) recipients from each treatment cohort. The percentage of mice with no tumors is shown in center of each chart. (C) Hematoxylin and eosin-stained sections of thymus and spleen of a secondary recipient from the 650.MND.hWASp cohort with a host-derived CD4⁺CD8⁺ lymphoma at ×60 magnification. The scale bar represents 10 μm. Blue arrowheads point to mitotic figures. (D) Flow cytometry plots of cells from the affected mouse shown in (C). Shown are CD4 and CD8 surface expression in indicated tissues. The recipient’s tumor origin was identified by congenic marker stain after gating on CD4⁺CD8⁺ thymic cells (plots at right). Percentages of live cells within each gate are indicated beneath the plots.